English

CYTEK BIOSCIENCES, INC.

EDGAR

CTKB Quarterly report (10-Q) · filed 2026-08-05

Annual consolidated revenue for 2025: about USD 201.5M, using the latest reported figures. The previous period, 2024, was about USD 200.5M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

48.1 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 48140000 USD Source

Operating margin

-23.68%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -11400000 USD Source
Revenue: 48140000 USD Source

Operating cash flow

1.37 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -1369000 USD Source
Operating Cash Flow: -2736000 USD Source

Free cash flow

-849 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -1369000 USD Source
Operating Cash Flow: -2736000 USD Source
Capital Expenditure: 4384000 USD Source
Capital Expenditure: 2168000 USD Source

Cash and cash equivalents: 73.8 million USD 2026-06-30 Source
Exact value

73846000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 130 million shares 2026-06-30 Source
Exact value

129982753 shares

Reported share-count change

2.20% · 2.8 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

127185113 shares · 2025-06-30· Source
129982753 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

207 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 52293000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 201493000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 139352000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 44135000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 48140000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-6.04 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -3915000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -17000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -4686000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -3915000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -2736000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -1369000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -2736000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

6.04 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 3083000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 2426000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 4084000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 3083000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 2168000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 4384000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 2168000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-12.1 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -3915000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -17000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -4686000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -3915000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -2736000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -1369000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -2736000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 3083000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 2426000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 4084000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 3083000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 2168000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 4384000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 2168000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-05.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2025-12-31
Operating income: 6 of 11 periods available· newest 2025-12-31
Net income: 6 of 11 periods available· newest 2025-12-31
Operating cash flow: 6 of 11 periods available· newest 2025-12-31
Capital expenditure: 6 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+0.5%

Prior period

USD 200.45 million

2024-01-01 – 2024-12-31
Current period

USD 201.49 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

201493000 − 200453000 = 1040000 USD

200453000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
201493000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · CYTEK BIOSCIENCES, INC. · 2025-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Year-over-year change in Revenue: 1040000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 201493000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#2306216 Filing: 000162828026012352 Input fundies:Revenue: 200453000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#2307192 Filing: 000162828026012352
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 60.52 million

Prior period

−USD 6.02 million

2024-01-01 – 2024-12-31
Current period

−USD 66.54 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-66539000 − -6020000 = -60519000 USD

-6020000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-66539000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · CYTEK BIOSCIENCES, INC. · 2025-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Year-over-year change in Net income: -60519000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -66539000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#2237592 Filing: 000162828026012352 Input fundies:NetIncome: -6020000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#2238366 Filing: 000162828026012352
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-118.5%

Prior period

USD 25.38 million

2024-01-01 – 2024-12-31
Current period

−USD 4.69 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-4686000 − 25379000 = -30065000 USD

25379000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-4686000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · CYTEK BIOSCIENCES, INC. · 2025-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Year-over-year change in Operating cash flow: -30065000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -4686000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1410928 Filing: 000162828026012352 Input fundies:OperatingCashFlow: 25379000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1411577 Filing: 000162828026012352
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+15.9%

Prior period

USD 3.53 million

2024-01-01 – 2024-12-31
Current period

USD 4.08 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

4084000 − 3525000 = 559000 USD

3525000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
4084000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · CYTEK BIOSCIENCES, INC. · 2025-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Year-over-year change in Capital expenditure: 559000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 4084000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1417982 Filing: 000162828026012352 Input fundies:CapitalExpenditure: 3525000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1418571 Filing: 000162828026012352
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 201.49 million 100% of revenue
Cost of revenue USD 97.03 million 48% of revenue
Operating expenses USD 144.84 million 72% of revenue
Operating income −USD 40.38 million −20% of revenue
Tax, interest and other Derived USD 26.16 million 13% of revenue
Net income −USD 66.54 million −33% of revenue

Cash

Operating cash flow −USD 4.69 million −2.3% of revenue
Capital expenditure USD 4.08 million 2% of revenue
Free cash flow Derived −USD 8.77 million −4.4% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Net income was higher than operating income, so the split is not drawn.
2021 Net income was higher than operating income, so the split is not drawn.
2022 Operating loss: operating costs were 101% of revenue.
2023 Operating loss: operating costs were 114% of revenue.
2024 Operating loss: operating costs were 110% of revenue.
2025 Operating loss: operating costs were 120% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	710000	-12949000 Derived	13659000	-5752000 Derived	19411000	13609000 Derived	Source 2020-01-01 – 2020-12-31: 710000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: 13659000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: 19411000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 15156000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1547000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	2181000	-6976000 Derived	9157000	6130000 Derived	3027000	266000 Derived	Source 2021-01-01 – 2021-12-31: 2181000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: 9157000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 3027000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 4630000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 4364000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	164036000	165840000 Derived	-1804000	-4288000 Derived	2484000	-21979000 Derived	Source 2022-01-01 – 2022-12-31: 164036000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -1804000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 2484000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -12231000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 9748000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	193015000	220860000 Derived	-27845000	-15697000 Derived	-12148000	633000 Derived	Source 2023-01-01 – 2023-12-31: 193015000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -27845000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -12148000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: 5281000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 4648000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	200453000	220976000 Derived	-20523000	-14503000 Derived	-6020000	21854000 Derived	Source 2024-01-01 – 2024-12-31: 200453000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -20523000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -6020000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: 25379000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 3525000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	201493000	241877000 Derived	-40384000	26155000 Derived	-66539000	-8770000 Derived	Source 2025-01-01 – 2025-12-31: 201493000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -40384000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -66539000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -4686000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 4084000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 201.5M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	710000	Revenue: 710000 Open source
20212021-12-31	Revenue	2181000	Revenue: 2181000 Open source
20222022-12-31	Revenue	164036000	Revenue: 164036000 Open source
20232023-12-31	Revenue	193015000	Revenue: 193015000 Open source
20242024-12-31	Revenue	200453000	Revenue: 200453000 Open source
20252025-12-31	Revenue	201493000	Revenue: 201493000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

0.5% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 710000 Open source
20212021-12-31	Year over year	207.2%	Revenue: 2181000 Open source Revenue: 710000 Open source
20222022-12-31	Year over year	7,421.1%	Revenue: 164036000 Open source Revenue: 2181000 Open source
20232023-12-31	Year over year	17.7%	Revenue: 193015000 Open source Revenue: 164036000 Open source
20242024-12-31	Year over year	3.9%	Revenue: 200453000 Open source Revenue: 193015000 Open source
20252025-12-31	Year over year	0.5%	Revenue: 201493000 Open source Revenue: 200453000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -20% 2025

Net margin -33% 2025

Free cash flow margin -4.4% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	1,923.8%	Operating Income: 13659000 Open source Revenue: 710000 Open source
20212021-12-31	Operating margin	419.9%	Operating Income: 9157000 Open source Revenue: 2181000 Open source
20222022-12-31	Operating margin	-1.1%	Operating Income: -1804000 Open source Revenue: 164036000 Open source
20232023-12-31	Operating margin	-14.4%	Operating Income: -27845000 Open source Revenue: 193015000 Open source
20242024-12-31	Operating margin	-10.2%	Operating Income: -20523000 Open source Revenue: 200453000 Open source
20252025-12-31	Operating margin	-20%	Operating Income: -40384000 Open source Revenue: 201493000 Open source
20202020-12-31	Net margin	2,733.9%	Net Income: 19411000 Open source Revenue: 710000 Open source
20212021-12-31	Net margin	138.8%	Net Income: 3027000 Open source Revenue: 2181000 Open source
20222022-12-31	Net margin	1.5%	Net Income: 2484000 Open source Revenue: 164036000 Open source
20232023-12-31	Net margin	-6.3%	Net Income: -12148000 Open source Revenue: 193015000 Open source
20242024-12-31	Net margin	-3%	Net Income: -6020000 Open source Revenue: 200453000 Open source
20252025-12-31	Net margin	-33%	Net Income: -66539000 Open source Revenue: 201493000 Open source
20202020-12-31	Free cash flow margin	1,916.8%	Revenue: 710000 Open source Operating Cash Flow: 15156000 Open source Capital Expenditure: 1547000 Open source
20212021-12-31	Free cash flow margin	12.2%	Revenue: 2181000 Open source Operating Cash Flow: 4630000 Open source Capital Expenditure: 4364000 Open source
20222022-12-31	Free cash flow margin	-13.4%	Revenue: 164036000 Open source Operating Cash Flow: -12231000 Open source Capital Expenditure: 9748000 Open source
20232023-12-31	Free cash flow margin	0.3%	Revenue: 193015000 Open source Operating Cash Flow: 5281000 Open source Capital Expenditure: 4648000 Open source
20242024-12-31	Free cash flow margin	10.9%	Revenue: 200453000 Open source Operating Cash Flow: 25379000 Open source Capital Expenditure: 3525000 Open source
20252025-12-31	Free cash flow margin	-4.4%	Revenue: 201493000 Open source Operating Cash Flow: -4686000 Open source Capital Expenditure: 4084000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -4.7M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	15156000	Operating Cash Flow: 15156000 Open source
20212021-12-31	Operating cash flow	4630000	Operating Cash Flow: 4630000 Open source
20222022-12-31	Operating cash flow	-12231000	Operating Cash Flow: -12231000 Open source
20232023-12-31	Operating cash flow	5281000	Operating Cash Flow: 5281000 Open source
20242024-12-31	Operating cash flow	25379000	Operating Cash Flow: 25379000 Open source
20252025-12-31	Operating cash flow	-4686000	Operating Cash Flow: -4686000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -8.8M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	13609000	Operating Cash Flow: 15156000 Open source Capital Expenditure: 1547000 Open source
20212021-12-31	Free cash flow	266000	Operating Cash Flow: 4630000 Open source Capital Expenditure: 4364000 Open source
20222022-12-31	Free cash flow	-21979000	Operating Cash Flow: -12231000 Open source Capital Expenditure: 9748000 Open source
20232023-12-31	Free cash flow	633000	Operating Cash Flow: 5281000 Open source Capital Expenditure: 4648000 Open source
20242024-12-31	Free cash flow	21854000	Operating Cash Flow: 25379000 Open source Capital Expenditure: 3525000 Open source
20252025-12-31	Free cash flow	-8770000	Operating Cash Flow: -4686000 Open source Capital Expenditure: 4084000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

26% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	19%	Total Liabilities: 41688000 Open source Total Assets: 219979000 Open source
20212021-12-31	Liabilities / assets	12.5%	Total Liabilities: 57920000 Open source Total Assets: 463305000 Open source
20222022-12-31	Liabilities / assets	18.1%	Total Liabilities: 93930000 Open source Total Assets: 519476000 Open source
20232023-12-31	Liabilities / assets	20.5%	Total Liabilities: 101393000 Open source Total Assets: 494457000 Open source
20242024-12-31	Liabilities / assets	20.8%	Total Liabilities: 103763000 Open source Total Assets: 499500000 Open source
20252025-12-31	Liabilities / assets	26%	Total Liabilities: 119803000 Open source Total Assets: 461542000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

5.04× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	7.86×	Current Assets: 208622000 Open source Current Liabilities: 26536000 Open source
20212021-12-31	Current assets / current liabilities	13.01×	Current Assets: 431733000 Open source Current Liabilities: 33181000 Open source
20222022-12-31	Current assets / current liabilities	9.26×	Current Assets: 454020000 Open source Current Liabilities: 49040000 Open source
20232023-12-31	Current assets / current liabilities	6.97×	Current Assets: 392060000 Open source Current Liabilities: 56226000 Open source
20242024-12-31	Current assets / current liabilities	5.86×	Current Assets: 396446000 Open source Current Liabilities: 67663000 Open source
20252025-12-31	Current assets / current liabilities	5.04×	Current Assets: 391996000 Open source Current Liabilities: 77804000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	USD 19.41 million Exact value Exact value: 19411000 USD 2020-01-01 – 2020-12-31: 19411000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYTEK BIOSCIENCES, INC. · 2020-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Net Income: 19411000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: 19411000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000095017023005610/ctkb-20221231.htm#4732334 Filing: 000095017023005610 The citation records this snapshot. The page link may show a newer release later.	USD 15.16 million Exact value Exact value: 15156000 USD 2020-01-01 – 2020-12-31: 15156000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYTEK BIOSCIENCES, INC. · 2020-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Operating Cash Flow: 15156000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 15156000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000095017023005610/ctkb-20221231.htm#2672663 Filing: 000095017023005610 The citation records this snapshot. The page link may show a newer release later.	USD 1.55 million Exact value Exact value: 1547000 USD 2020-01-01 – 2020-12-31: 1547000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CYTEK BIOSCIENCES, INC. · 2020-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Capital Expenditure: 1547000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1547000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000095017023005610/ctkb-20221231.htm#2690369 Filing: 000095017023005610 The citation records this snapshot. The page link may show a newer release later.	USD 13.61 million Calculation and evidence 15156000 − 1547000 USD Exact free cash flow: 13609000 USD 2020-01-01 – 2020-12-31: 15156000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1547000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CYTEK BIOSCIENCES, INC. · 2020-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Free cash flow: 13609000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 15156000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000095017023005610/ctkb-20221231.htm#2672663 Filing: 000095017023005610 Input fundies:CapitalExpenditure: 1547000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000095017023005610/ctkb-20221231.htm#2690369 Filing: 000095017023005610 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 3.03 million Exact value Exact value: 3027000 USD 2021-01-01 – 2021-12-31: 3027000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYTEK BIOSCIENCES, INC. · 2021-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Net Income: 3027000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 3027000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828024010933/ctkb-20231231.htm#2195128 Filing: 000162828024010933 The citation records this snapshot. The page link may show a newer release later.	USD 4.63 million Exact value Exact value: 4630000 USD 2021-01-01 – 2021-12-31: 4630000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYTEK BIOSCIENCES, INC. · 2021-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Operating Cash Flow: 4630000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4630000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828024010933/ctkb-20231231.htm#1401017 Filing: 000162828024010933 The citation records this snapshot. The page link may show a newer release later.	USD 4.36 million Exact value Exact value: 4364000 USD 2021-01-01 – 2021-12-31: 4364000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CYTEK BIOSCIENCES, INC. · 2021-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Capital Expenditure: 4364000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4364000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828024010933/ctkb-20231231.htm#1407998 Filing: 000162828024010933 The citation records this snapshot. The page link may show a newer release later.	USD 266,000 Calculation and evidence 4630000 − 4364000 USD Exact free cash flow: 266000 USD 2021-01-01 – 2021-12-31: 4630000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 4364000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CYTEK BIOSCIENCES, INC. · 2021-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Free cash flow: 266000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 4630000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828024010933/ctkb-20231231.htm#1401017 Filing: 000162828024010933 Input fundies:CapitalExpenditure: 4364000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828024010933/ctkb-20231231.htm#1407998 Filing: 000162828024010933 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	USD 2.48 million Exact value Exact value: 2484000 USD 2022-01-01 – 2022-12-31: 2484000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYTEK BIOSCIENCES, INC. · 2022-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Net Income: 2484000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: 2484000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828025008780/ctkb-20241231.htm#2189190 Filing: 000162828025008780 The citation records this snapshot. The page link may show a newer release later.	−USD 12.23 million Exact value Exact value: -12231000 USD 2022-01-01 – 2022-12-31: -12231000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYTEK BIOSCIENCES, INC. · 2022-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Operating Cash Flow: -12231000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12231000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828025008780/ctkb-20241231.htm#1388883 Filing: 000162828025008780 The citation records this snapshot. The page link may show a newer release later.	USD 9.75 million Exact value Exact value: 9748000 USD 2022-01-01 – 2022-12-31: 9748000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CYTEK BIOSCIENCES, INC. · 2022-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Capital Expenditure: 9748000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9748000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828025008780/ctkb-20241231.htm#1395884 Filing: 000162828025008780 The citation records this snapshot. The page link may show a newer release later.	−USD 21.98 million Calculation and evidence -12231000 − 9748000 USD Exact free cash flow: -21979000 USD 2022-01-01 – 2022-12-31: -12231000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 9748000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CYTEK BIOSCIENCES, INC. · 2022-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Free cash flow: -21979000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12231000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828025008780/ctkb-20241231.htm#1388883 Filing: 000162828025008780 Input fundies:CapitalExpenditure: 9748000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828025008780/ctkb-20241231.htm#1395884 Filing: 000162828025008780 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 12.15 million Exact value Exact value: -12148000 USD 2023-01-01 – 2023-12-31: -12148000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYTEK BIOSCIENCES, INC. · 2023-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Net Income: -12148000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -12148000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#2239140 Filing: 000162828026012352 The citation records this snapshot. The page link may show a newer release later.	USD 5.28 million Exact value Exact value: 5281000 USD 2023-01-01 – 2023-12-31: 5281000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYTEK BIOSCIENCES, INC. · 2023-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Operating Cash Flow: 5281000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 5281000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1412224 Filing: 000162828026012352 The citation records this snapshot. The page link may show a newer release later.	USD 4.65 million Exact value Exact value: 4648000 USD 2023-01-01 – 2023-12-31: 4648000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CYTEK BIOSCIENCES, INC. · 2023-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Capital Expenditure: 4648000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4648000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1419161 Filing: 000162828026012352 The citation records this snapshot. The page link may show a newer release later.	USD 633,000 Calculation and evidence 5281000 − 4648000 USD Exact free cash flow: 633000 USD 2023-01-01 – 2023-12-31: 5281000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 4648000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CYTEK BIOSCIENCES, INC. · 2023-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Free cash flow: 633000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 5281000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1412224 Filing: 000162828026012352 Input fundies:CapitalExpenditure: 4648000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1419161 Filing: 000162828026012352 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 6.02 million Exact value Exact value: -6020000 USD 2024-01-01 – 2024-12-31: -6020000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYTEK BIOSCIENCES, INC. · 2024-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Net Income: -6020000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6020000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#2238366 Filing: 000162828026012352 The citation records this snapshot. The page link may show a newer release later.	USD 25.38 million Exact value Exact value: 25379000 USD 2024-01-01 – 2024-12-31: 25379000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYTEK BIOSCIENCES, INC. · 2024-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Operating Cash Flow: 25379000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 25379000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1411577 Filing: 000162828026012352 The citation records this snapshot. The page link may show a newer release later.	USD 3.53 million Exact value Exact value: 3525000 USD 2024-01-01 – 2024-12-31: 3525000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CYTEK BIOSCIENCES, INC. · 2024-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Capital Expenditure: 3525000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3525000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1418571 Filing: 000162828026012352 The citation records this snapshot. The page link may show a newer release later.	USD 21.85 million Calculation and evidence 25379000 − 3525000 USD Exact free cash flow: 21854000 USD 2024-01-01 – 2024-12-31: 25379000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 3525000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CYTEK BIOSCIENCES, INC. · 2024-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Free cash flow: 21854000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 25379000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1411577 Filing: 000162828026012352 Input fundies:CapitalExpenditure: 3525000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1418571 Filing: 000162828026012352 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 66.54 million Exact value Exact value: -66539000 USD 2025-01-01 – 2025-12-31: -66539000 USD Inspect Net Income Open source Share or cite Citation for Net Income · CYTEK BIOSCIENCES, INC. · 2025-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Net Income: -66539000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -66539000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#2237592 Filing: 000162828026012352 The citation records this snapshot. The page link may show a newer release later.	−USD 4.69 million Exact value Exact value: -4686000 USD 2025-01-01 – 2025-12-31: -4686000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · CYTEK BIOSCIENCES, INC. · 2025-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Operating Cash Flow: -4686000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4686000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1410928 Filing: 000162828026012352 The citation records this snapshot. The page link may show a newer release later.	USD 4.08 million Exact value Exact value: 4084000 USD 2025-01-01 – 2025-12-31: 4084000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · CYTEK BIOSCIENCES, INC. · 2025-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Capital Expenditure: 4084000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4084000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1417982 Filing: 000162828026012352 The citation records this snapshot. The page link may show a newer release later.	−USD 8.77 million Calculation and evidence -4686000 − 4084000 USD Exact free cash flow: -8770000 USD 2025-01-01 – 2025-12-31: -4686000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 4084000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · CYTEK BIOSCIENCES, INC. · 2025-12-31 CYTEK BIOSCIENCES, INC. (edgar:1831915) Free cash flow: -8770000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:41:50Z Snapshot: ce2ee48b33bb7a704db1b1ada8aa5a8dda1e83276365e8f7c133218eedfaf4ce Dimensions: Consolidated View: https://fundies.io/companies/edgar/1831915?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -4686000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1410928 Filing: 000162828026012352 Input fundies:CapitalExpenditure: 4084000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1831915/000162828026012352/ctkb-20251231.htm#1417982 Filing: 000162828026012352 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

25 filings · 2,267 latest values · 2,267 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001831915, 1831915, CTKB, edgar:1831915

Also known as CYTEK BIOSCIENCES, INC., Cytek BioSciences, Inc., Cytek Biosciences, Inc.

CYTEK BIOSCIENCES, INC.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation